US to impose inflation fines on first set of drugs, lowering costs

[March 15, 2023]  By Ahmed Aboulenein

WASHINGTON (Reuters) - The U.S. government will subject 27 drugs to inflation penalties, it announced on Wednesday, meaning people on Medicare will pay less out-of-pocket by $2 to as high as $390 per average dose starting April 1.

President Joe Biden's signature Inflation Reduction Act includes a provision penalizing drugmakers for charging prices that rise faster than inflation for people with disabilities or age 65 and older on the government's Medicare health program.

"Starting on April 1, Medicare beneficiaries will pay lower coinsurance for Part B drugs that raise prices faster than inflation," White House Domestic Policy Adviser Susan Rice told reporters on a press call.

The list includes AbbVie Inc's blockbuster arthritis drug Humira, Gilead Sciences Inc's Car-T cancer therapy Yescarta and Seagen Inc's targeted cancer therapy Padcev, the White House said in a fact sheet.

Companies that raise prices higher than the inflation rate will be required to pay Medicare the difference in the form of a rebate. Those that fail to pay the rebate will face a penalty equaling 125% of the rebate amount.

U.S. President Joe Biden participates in a bilateral meeting with Australian Prime Minister Anthony Albanese (not pictured) at Navy Gateway Inns and Suites, in San Diego, California U.S., March 13, 2023. REUTERS/Leah Millis/File Photo

The government will start invoicing the companies for the rebates in 2025 but Medicare will start reducing out-pocket-costs for members in April.

Medicare began examining the price increases in October 2022 for Medicare Part B drugs, often used in the hospital, that are complicated biologic drugs or drugs with only one manufacturer.

The government will update the list of drugs each quarter.

Price increases for half of all drugs covered by Medicare outpaced inflation from 2019 to 2020, which averaged 1% that year. A third of those had price jumps of over 7.5%.

The Department of Health and Human Services (HHS) will also release on Wednesday initial guidance on how its Medicare prescription drug negotiation process will work, Rice said.

(Reporting by Ahmed Aboulenein; Editing by Josie Kao)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.